Lang Yu
Wuhan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab.
Journal: Clinical, cosmetic and investigational dermatology
Published: January 28, 2026
Efficacy and Safety of Abrocitinib in an Elderly Chinese Population with Moderate-to-Severe Atopic Dermatitis: A Non-randomized Controlled Trial.
Journal: Acta dermato-venereologica
Published: June 22, 2025
Exploring telitacicept in a patient with pemphigus vulgaris.
Journal: The British journal of dermatology
Published: October 16, 2024
Case report: Managing pemphigus foliaceus using apremilast without systemic glucocorticosteroids or immunosuppressive agents.
Journal: Frontiers in immunology
Published: March 27, 2024
Abrocitinib for prurigo nodularis: Clinical efficacy and safety profile.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 27, 2024
Ineffectiveness of apremilast in moderate-to-severe pemphigus: A case series of three patients.
Journal: The Australasian journal of dermatology
Published: December 29, 2023
Treatment of pemphigoid vegetans with abrocitinib.
Journal: Clinical and experimental dermatology
Published: September 21, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026